New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTSUSS, MERU, HPTX, CGEN, AMC, SCSS, SHW, PPG, SU, IMO, EPGNY, CVE, TPX, VAL, TLM, RKUS, ITT, ECA, CTIC, BOFI, AGU, RPMOn The Fly: Analyst Initiation Summary
AMC Entertainment (AMC) initiated with an Equal Weight at Barclays... Canadian Natural (CNQ) initiated with an Outperformer at CIBC... Cell Therapeutics (CTIC) initiated with a Hold at WallachBeth... Cenovus Energy (CVE) initiated with a Sector Performer at CIBC... Compugen (CGEN) initiated with a Buy at Jefferies... Encana (ECA) initiated with a Sector Performer at CIBC... Epigenomics (EPGNY) initiated with a Buy at Maxim... Hyperion Therapeutics (HPTX) initiated with a Buy at Cantor... ITT Corp. (ITT) initiated with a Buy at SunTrust... Imperial Oil (IMO) initiated with a Sector Performer at CIBC... Mattress Firm (MFRM) initiated with a Buy at Jefferies... Meru Networks (MERU) initiated with a Buy at Mizuho... Ruckus Wireless (RKUS) initiated with a Buy at Mizuho... Suncor (SU) initiated with an Outperformer at CIBC... Susser Holdings (SUSS) initiated with a Hold at Jefferies... Talisman Energy (TLM) initiated with an Underperformer at CIBC... PPG Industries (PPG) coverage assumed with an Equal Weight at Morgan Stanley... RPM (RPM) coverage assumed with an Overweight at Morgan Stanley... Valspar (VAL) coverage assumed with an Underweight at Morgan Stanley... Sherwin-Williams (SHW) coverage assumed with an Overweight at Morgan Stanley... Agrium (AGU) coverage resumed with an Equal Weight at Morgan Stanley... Canadian Natural (CNQ) initiated with an Overweight at Morgan Stanley... Tempur Sealy (TPX) initiated with a Neutral at Nomura... Select Comfort (SCSS) initiated with a Neutral at Nomura... Mattress Firm (MFRM) initiated with a Buy at Nomura... Bofi Holding (BOFI) initiated with a Neutral at Sterne Agee.
News For AMC;CTIC;CVE;CGEN;ECA;EPGNY;HPTX;ITT;IMO;MERU;RKUS;SU;SUSS;TLM;PPG;RPM;VAL;SHW;AGU;TPX;SCSS;BOFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 19, 2015
12:32 EDTSHWSherwin-Williams management to meet with Sterne Agee
Subscribe for More Information
10:32 EDTTPXHigh option volume stocks:
Subscribe for More Information
February 18, 2015
13:28 EDTTLMTalisman Energy receives shareholder approval for acquisition by Repsol
Subscribe for More Information
11:33 EDTSHWSherwin-Williams increases dividend 22% to 67c per share
Subscribe for More Information
10:42 EDTTLMOptions with increasing implied volatility: NLNK TLM
Subscribe for More Information
10:08 EDTTLMTalisman Energy to host special shareholder meeting
Subscribe for More Information
08:20 EDTTPXTempur Sealy says strategic priorities include expanding margins
Says strategic priorities include accretive acquisitions of licensees, JVs, expanding distribution, expanding margins.
08:19 EDTTPXTempur Sealy sees FY15 adjusted EPS growth 12%-27%
Sees FY15 adjusted EPS growth 12%-27% and net sales growth 5.5%-8.5%, as adjusted for FX. Not adjusted for FX, sees FY15 adjusted EPS growth 2%-17%, net sales growth 2%-5%.
08:17 EDTTPXTempur Sealy says targeting 15% annual base adjusted EPS growth 2015-2018
Says targeting 6% annual base sales growth 2015-2018. Targeting 50bps annual base operating margin improvement 2015-2018. Comments from Investor Day presentation slides.
07:56 EDTAMCAMC Entertainment price target raised to $37 from $28 at FBR Capital
Subscribe for More Information
07:05 EDTCVECenovus Energy reports C$1.5B bought deal common share financing
Subscribe for More Information
07:05 EDTAMCAMC Entertainment price target raised to $36 from $30 at Stifel
Subscribe for More Information
05:42 EDTAMCAMC Entertainment price target raised to $35 from $28 at Piper Jaffray
Subscribe for More Information
February 17, 2015
18:06 EDTTLMPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:13 EDTSU, TLMPoint72 gives quarterly update on stakes
Subscribe for More Information
16:06 EDTAMCAMC Entertainment reports Q4 EPS 30c, consensus 20c
Reports Q4 revenue $712.2M, consensus $712.08M.
13:36 EDTTPXTempur Sealy says 'disappointed' in H Partners going public
Subscribe for More Information
07:42 EDTTPXTempur Sealy shareholder H Partners demands leadership, board changes
Subscribe for More Information
06:36 EDTTPXH Partners to demand CEO change at Tempur Sealy, WSJ says
Subscribe for More Information
05:28 EDTHPTXHyperion enters into agreement with CBI, Yeda regarding DiaPep277
Hyperion Therapeutics announced that it has amicably resolved its disputes, and entered into a completion of phase III clinical trial, option and mutual release agreement with Clal Biotechnology Industries, or CBI, and Yeda Research and Development regarding DiaPep277, a product candidate developed by Andromeda Biotech, a company which Hyperion acquired from CBI in June 2014. As announced in its September 8, 2014 press release, Hyperion will complete the ongoing DIA-AID 2 phase 3 clinical trial of DiaPep277 to treat new onset Type 1 diabetes and will not take DiaPep277 forward beyond completion of the DIA-AID 2 trial. Hyperion's estimated budget for completion of the DIA-AID 2 trial remains unchanged at $10.5M. CBI will have an option to acquire Andromeda, which option expires September 30. CBI will pay a nonrefundable option payment of $2.5M at signing, payable in shares of Hyperion stock currently held by CBI. Subject to agreed restrictions, a steering committee consisting of representatives from CBI, Yeda and Hyperion, will oversee and direct the completion of the trial, the analysis of its results, and interactions with regulatory authorities. Hyperion intends to use the option payment to offset any potential increases to the DIA-AID2 trial budget incurred at the steering committee's direction. Any increases to this budget beyond $2.25M , if incurred at the steering committee's direction, will be reimbursed by CBI. CBI exercises the option, CBI will pay an option exercise price of $3.5M, payable in shares of Hyperion stock currently held by CBI. In addition, if the option is exercised, then Andromeda will be obligated to pay Hyperion future contingent payments if and to the extent it or its shareholders receive revenues or certain other proceeds, which are capped at $36.5M. This amount, together with the option exercise price that Hyperion may receive, approximates the total amount Hyperion will have invested in Andromeda by the option exercise date. If CBI does not exercise the option, the Agreement provides for DiaPep277 intellectual property rights to revert to Yeda.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use